JP2018537966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537966A5 JP2018537966A5 JP2018521308A JP2018521308A JP2018537966A5 JP 2018537966 A5 JP2018537966 A5 JP 2018537966A5 JP 2018521308 A JP2018521308 A JP 2018521308A JP 2018521308 A JP2018521308 A JP 2018521308A JP 2018537966 A5 JP2018537966 A5 JP 2018537966A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide chain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 644
- 229920001184 polypeptide Polymers 0.000 claims 248
- 102000004196 processed proteins & peptides Human genes 0.000 claims 248
- 108090000765 processed proteins & peptides Proteins 0.000 claims 248
- 102000023732 binding proteins Human genes 0.000 claims 39
- 108091008324 binding proteins Proteins 0.000 claims 39
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 239000013598 vector Substances 0.000 claims 13
- 238000006467 substitution reaction Methods 0.000 claims 10
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 8
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 108090000288 Glycoproteins Proteins 0.000 claims 4
- 102000003886 Glycoproteins Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 238000011225 antiretroviral therapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021016190A JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2023061823A JP7724814B2 (ja) | 2015-10-25 | 2023-04-06 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246113P | 2015-10-25 | 2015-10-25 | |
| US62/246,113 | 2015-10-25 | ||
| EP16305211 | 2016-02-24 | ||
| EP16305211.1 | 2016-02-24 | ||
| US201662322029P | 2016-04-13 | 2016-04-13 | |
| US62/322,029 | 2016-04-13 | ||
| US201662331169P | 2016-05-03 | 2016-05-03 | |
| US62/331,169 | 2016-05-03 | ||
| PCT/US2016/058540 WO2017074878A1 (en) | 2015-10-25 | 2016-10-24 | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016190A Division JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537966A JP2018537966A (ja) | 2018-12-27 |
| JP2018537966A5 true JP2018537966A5 (enExample) | 2019-11-21 |
| JP7169190B2 JP7169190B2 (ja) | 2022-11-10 |
Family
ID=55588187
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521308A Active JP7169190B2 (ja) | 2015-10-25 | 2016-10-24 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2021016190A Active JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2023061823A Active JP7724814B2 (ja) | 2015-10-25 | 2023-04-06 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016190A Active JP7328267B2 (ja) | 2015-10-25 | 2021-02-04 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
| JP2023061823A Active JP7724814B2 (ja) | 2015-10-25 | 2023-04-06 | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 |
Country Status (31)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| EP3778630A1 (en) * | 2014-02-28 | 2021-02-17 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
| NZ781602A (en) | 2015-10-25 | 2025-07-25 | Sanofi Sa | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
| AU2016349392B2 (en) * | 2015-11-03 | 2023-07-13 | The Trustees Of Columbia University In The City Of New York | Neutralizing antibodies to HIV-1 gp41 and their use |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| EP4257193B1 (en) | 2016-04-13 | 2025-12-31 | Sanofi | TRISPECIFIC AND/OR TRIVALENT LINKING PROTEINS |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| KR20240049621A (ko) | 2017-02-17 | 2024-04-16 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| EP3601334A4 (en) * | 2017-03-27 | 2021-03-31 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
| EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
| CN120058938A (zh) | 2017-10-10 | 2025-05-30 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
| EP3728310A1 (en) * | 2017-12-18 | 2020-10-28 | VIIV Healthcare UK (No.5) Limited | Antigen binding polypeptides |
| CN111819196B (zh) * | 2017-12-21 | 2022-10-28 | 纽约市哥伦比亚大学理事会 | 双特异性hiv-1中和抗体 |
| IL275536B2 (en) | 2018-01-12 | 2025-06-01 | Genzyme Corp | Methods for quantification of polypeptides |
| US11845788B2 (en) | 2018-05-22 | 2023-12-19 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (HIV) |
| KR20210075129A (ko) | 2018-10-09 | 2021-06-22 | 사노피 | 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법 |
| EP3883962A4 (en) * | 2018-11-21 | 2023-04-12 | Beth Israel Deaconess Medical Center, Inc. | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| PH12021500041A1 (en) * | 2019-04-09 | 2022-06-06 | Sanofi Sa | Trispecific binding proteins, methods, and uses thereof |
| TW202104274A (zh) | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 |
| AU2020371500A1 (en) | 2019-10-25 | 2022-06-09 | Sanofi | Methods for analyzing chain mispairing in multispecific binding proteins |
| WO2021203103A2 (en) * | 2020-04-03 | 2021-10-07 | Somasekar Seshagiri | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
| MX2023002194A (es) * | 2020-08-25 | 2023-03-03 | Gilead Sciences Inc | Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso. |
| EP4408892A4 (en) * | 2021-09-29 | 2025-11-19 | Modex Therapeutics Inc | Antigen-binding polypeptides, antigen-binding polypeptide complexes, and their methods of use in HIV |
| CN118591388A (zh) * | 2021-09-29 | 2024-09-03 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| CA3232357A1 (en) * | 2021-09-29 | 2023-04-06 | Mark GRECI | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof |
| WO2025109206A1 (en) | 2023-11-22 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025108551A1 (en) | 2023-11-23 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025238419A1 (en) | 2024-05-17 | 2025-11-20 | Sanofi | Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| MXPA03006358A (es) | 2001-01-17 | 2004-12-02 | Trubion Pharmaceuticals Inc | Proteinas de fusion dominio de enlace-inmunoglobulina. |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US20050163782A1 (en) | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US9175070B2 (en) | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
| JP6093696B2 (ja) | 2010-06-09 | 2017-03-08 | ゲンマブ エー／エス | ヒトｃｄ３８に対する抗体 |
| CN103282385A (zh) | 2010-11-12 | 2013-09-04 | 美国洛克菲勒大学 | 用于hiv治疗的融合蛋白 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2012255266B2 (en) * | 2011-05-17 | 2017-05-25 | California Institute Of Technology | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
| CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| BR112014010823B1 (pt) | 2011-11-07 | 2021-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial |
| EP2788376B1 (en) | 2011-12-08 | 2018-10-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HK1215950A1 (zh) * | 2012-09-25 | 2016-09-30 | 艾科诺斯科技股份有限公司 | 异源二聚免疫球蛋白的纯化 |
| CN104955847A (zh) | 2012-12-04 | 2015-09-30 | 马里兰州大学(巴尔的摩) | HIV-1 Env结合抗体、融合蛋白及其使用方法 |
| KR20230156146A (ko) | 2012-12-13 | 2023-11-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ｄｎａ 항체 작제물 및 그 이용 방법 |
| US20140213772A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US20140242077A1 (en) * | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| PT2961771T (pt) * | 2013-02-26 | 2020-02-28 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea |
| WO2014144299A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
| DK3189132T3 (da) | 2014-09-04 | 2020-08-10 | Stemcell Tech Inc | Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion |
| LT3247725T (lt) | 2015-01-23 | 2020-10-12 | Sanofi | Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123 |
| EP3998471A1 (en) | 2015-05-20 | 2022-05-18 | Quantum-si Incorporated | Method of determining the sequence of a nucleic acid using time resolved luminescence |
| WO2016196740A1 (en) | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
| WO2017053556A1 (en) | 2015-09-22 | 2017-03-30 | The Trustees Of The University Of Pennsylvania | Method of redirecting t cells to treat hiv infection |
| NZ781602A (en) | 2015-10-25 | 2025-07-25 | Sanofi Sa | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
| CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| CU20180062A7 (es) | 2015-12-15 | 2018-08-06 | Gilead Sciences Inc | Anticuerpos neutralizadores del virus de inmunodeficiencia humana |
| EP4257193B1 (en) | 2016-04-13 | 2025-12-31 | Sanofi | TRISPECIFIC AND/OR TRIVALENT LINKING PROTEINS |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| US12234479B2 (en) | 2016-12-30 | 2025-02-25 | Cytocares (Shanghai) Inc. | Bifunctional molecule and use thereof |
| KR20240049621A (ko) | 2017-02-17 | 2024-04-16 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| EP3601334A4 (en) | 2017-03-27 | 2021-03-31 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
| CN120058938A (zh) | 2017-10-10 | 2025-05-30 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
| KR20210075129A (ko) | 2018-10-09 | 2021-06-22 | 사노피 | 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 NZ NZ781602A patent/NZ781602A/en unknown
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en not_active Ceased
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 BR BR112018008011-0A patent/BR112018008011A2/en not_active Application Discontinuation
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-24 KR KR1020187014534A patent/KR102687212B1/ko active Active
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
- 2016-10-25 TW TW113100534A patent/TW202442675A/zh unknown
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP7724814B2/ja active Active
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
- 2024-11-26 US US18/960,890 patent/US20250312475A1/en active Pending